Carregant...
ACTR-38. SAFETY AND EFFECTIVENESS OF BEVACIZUMAB IN JAPANESE PATIENTS WITH MALIGNANT GLIOMA: POST-MARKETING SURVEILLANCE RESULTS
OBJECTIVES: In Japan, when bevacizumab was approved for malignant glioma patients in 2013, there were limited data on Japanese patients. In the global P3 AVAglio study, the incidence of cerebral hemorrhage, including tumor-related bleeding, and infections was higher in patients who received bevacizu...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692943/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.029 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|